8-K: Clearside Biomedical Highlights Suprachoroidal Delivery Potential in Webinar

Clearside Biomedical hosted a webinar emphasizing the versatility and potential of its suprachoroidal drug delivery platform, including updates on its clinical programs.

Summary

• Clearside Biomedical held a virtual webinar on July 24, 2024, focusing on suprachoroidal drug delivery.
• The webinar featured presentations from key opinion leaders and Clearside management.
• The company highlighted its leadership in suprachoroidal delivery, with an FDA-approved product, XIPERE, and multiple collaborations.
• Clearside's clinical program targets the multi-billion dollar wet AMD market, with Phase 2b trial data expected in late Q3 2024.
• The company's suprachoroidal injection platform is being used in various programs, including treatments for uveitic macular edema and diabetic macular edema.
• Real-world data from the IRIS registry shows that 87.7% of eyes treated with suprachoroidal triamcinolone acetonide did not require rescue therapy with injected or implanted corticosteroids within 24 weeks.
• Clearside is developing CLS-AX, a potent pan-VEGF inhibitor for wet AMD, using the same suprachoroidal microinjector as XIPERE.
• The ODYSSEY Phase 2b trial for CLS-AX is on track to release top-line data in late Q3 2024, with no drug-related serious adverse events reported to date.
• Clearside is also exploring the potential of suprachoroidal delivery for geographic atrophy, a condition with limited treatment options.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on Clearside's technology and clinical programs, with strong real-world data and no reported safety issues in the ongoing trial. The company is positioning itself as a leader in a promising field.

Positives

• Clearside has a proven track record in suprachoroidal delivery with an FDA-approved product.
• The company has a proprietary microinjector with significant clinical experience and ISO certified commercial scale manufacturing.
• Real-world data supports the durability of suprachoroidal injections.
• The CLS-AX program has the potential to reduce the treatment burden for wet AMD patients.
• The ODYSSEY trial is progressing well with no drug-related serious adverse events reported.
• Suprachoroidal delivery offers a less invasive approach with potential for longer duration of action.

Negatives

• The presentation includes forward-looking statements that are subject to risks and uncertainties.
• The company's future success depends on the results of clinical trials and regulatory approvals.
• The company faces competition from other companies developing treatments for retinal diseases.
• The presentation notes that some patients may experience a sensation of pressure wave during suprachoroidal injections.

Risks

• The company's plans to develop and commercialize product candidates are subject to risks.
• Adverse differences between preliminary and final data could impact results.
• The company's ability to obtain and maintain regulatory approvals is not guaranteed.
• Clinical trials may not be predictive of future results.
• The company's estimates regarding future revenue, expenses, and capital requirements are subject to uncertainty.
• The company may need additional financing in the future.

Future Outlook

Clearside anticipates releasing top-line data from the ODYSSEY Phase 2b trial in late Q3 2024 and continues to explore the potential of suprachoroidal delivery for various retinal diseases.

Management Comments

• George Lasezkay, President & CEO, highlighted Clearside's leadership in suprachoroidal delivery.
• Victor Chong, Chief Medical Officer, discussed pipeline opportunities and the potential of suprachoroidal delivery for geographic atrophy.
• David Brown, Director of Research, Retina Consultants Houston, provided a large practice view of suprachoroidal delivery.

Industry Context

The webinar highlights the growing interest in suprachoroidal drug delivery as a potential alternative to traditional intravitreal injections, particularly for conditions like wet AMD and geographic atrophy where current treatments have limitations. The company is positioning itself as a leader in this emerging field.

Comparison to Industry Standards

• Clearside's XIPERE is the first FDA-approved product for suprachoroidal administration, setting a benchmark in this delivery method.
• The company's CLS-AX program aims to reduce the frequency of injections compared to current anti-VEGF therapies like LUCENTIS (12x/year), EYLEA (6x/year), and VABYSMO (3-6x/year).
• The ODYSSEY trial design incorporates flexible dosing based on disease activity, which is more aligned with real-world clinical practice than fixed dosing regimens used in some other trials.
• The company is exploring suprachoroidal delivery for geographic atrophy, a condition where intravitreal biologics have failed, suggesting a potential advantage over other approaches.

Stakeholder Impact

• Shareholders may benefit from the potential success of Clearside's clinical programs and commercialization efforts.
• Patients with retinal diseases may benefit from new and improved treatment options.
• Physicians may benefit from the ease of use and potential advantages of suprachoroidal delivery.
• The company's employees may benefit from the growth and success of the company.

Next Steps

• Clearside will release top-line data from the ODYSSEY Phase 2b trial in late Q3 2024.
• The company will continue to explore the potential of suprachoroidal delivery for various retinal diseases.
• Clearside will continue to develop and potentially commercialize its product candidates.

Key Dates

Keywords

suprachoroidal delivery, wet AMD, uveitic macular edema, CLS-AX, XIPERE, geographic atrophy, retinal diseases, drug delivery, clinical trials, ophthalmology